Acute transverse myelitis after inactivated COVID-19 vaccine

Erdem, Nazan Şimşek; Demirci, Seden; Özel, Tuğba; Mamadova, Khalida; Karaali̇, Kami̇l; Çelik, T.; Uslu, Ferda Ilgen; Özkaynak, Sehür Sibel

doi:10.18071/isz.74.0273

Cited by 29 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 2 ] Recently, several cases of transverse myelitis from 1 to 14 days after COVID-19 vaccination have been also reported. [ 3 – 9 ] A single case of transverse myelitis following the mRNA-1273 COVID-19 vaccine was recently reported by Khan et al [ 8 ] Notably, the present case showed several differences from the previous case, including:…”

Section: Discussionmentioning

confidence: 62%

See 1 more Smart Citation

Acute autoimmune transverse myelitis following COVID-19 vaccination

Hirose¹,

Hara²,

Koda³

et al. 2021

Medicine

View full text Add to dashboard Cite

Rationale: Transverse myelitis is an infectious or noninfectious inflammatory spinal cord syndrome. We report a rare case of transverse myelitis following vaccination against COVID-19. Patient concerns: A 70-year-old male presented with progressive sensorimotor dysfunction of the bilateral lower limbs 7 days after receiving the mRNA-1273 vaccine against COVID-19. Spinal magnetic resonance imaging revealed intramedullary lesions with gadolinium enhancement on the Th1/2 and Th5/6 vertebral levels. Cerebrospinal fluid (CSF) testing showed a mildly increased level of total protein and positive oligoclonal bands (OCB). Diagnosis: The patient was diagnosed with acute transverse myelitis. Intervention: The patient received 5 days of intravenous methylprednisolone pulse (1000 mg/day) followed by oral prednisolone (30 mg/day with gradual tapering). Outcomes: The patient fully recovered from muscle weakness of the lower limbs. He was discharged from our hospital and able to independently walk without unsteadiness. Lesson: This is a rare case of transverse myelitis following COVID-19 vaccination. Positive OCB in CSF in the present case highlights the possibility of autoimmune processes, including polyclonal activation of B lymphocytes, following vaccination.

show abstract

Section: Discussionmentioning

confidence: 62%

“…Recently, several cases of transverse myelitis from 1 to 14 days after COVID-19 vaccination have been also reported. [ 3 – 9 ] Here we report a rare case presenting with transverse myelitis following COVID-19 vaccination with mRNA-1273, Moderna.…”

Section: Introductionmentioning

confidence: 98%

Acute autoimmune transverse myelitis following COVID-19 vaccination

Hirose¹,

Hara²,

Koda³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…For COVID-19 vaccine-related events, a total of 51,755,447 doses of COVID-19 vaccines were administered until March 2021 and nine cases of related ATM were reported among 9442 adverse events; the incidence is approximately 1.739/per million people [ 2 ]. After the literature review, we summarized the published case reports of SARS-CoV-2 vaccination-related transverse myelitis with detailed clinical information in Table 1 [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

Acute Transverse Myelitis after COVID-19 Vaccination

et al. 2021

View full text Add to dashboard Cite

The adverse effects of the COVID-19 vaccine have been discovered as the rapid application of the vaccines continues. Neurological complications such as transverse myelitis raise concerns as cases were observed in clinical trials. Transverse myelitis is a rare immune-mediated disease with spinal cord neural injury, resulting in neurological deficits in the motor, sensory, and autonomic system. Vaccine-related transverse myelitis is even rarer. We present a case of acute transverse myelitis after vaccination against COVID-19 with the ChAdOx1 nCOV-19 vaccine (AZD1222), which was the first case reported in Taiwan. Although it rarely occurs, post-vaccination neurological complications should not be ignored. As the pandemic of SARS-COV-2 continues to spread and concern about vaccination efficacy and safety rises, heterologous vaccination were implemented in health public policy in several countries. A literature review of several clinical trials shows promising effects of mix-and-match vaccination. Further study on different combinations of vaccines can be expected.

show abstract

“…The swelling and pain was reported to be resolved 2 days post treatment and at follow--up one month later, the condition of the joint was found to be normal (62). A 78--year old woman presented for treatment with tetraparesis, paresthesias of bilateral upper extremities, and urinary retention of one--day duration (63). Three weeks before symptom onset, the patient had been vaccinated with CoronaVac (63).…”

Section: (33) Inactivated-virus Sars-cov-2 Vaccine Candidatesmentioning

confidence: 99%

“…A 78--year old woman presented for treatment with tetraparesis, paresthesias of bilateral upper extremities, and urinary retention of one--day duration (63). Three weeks before symptom onset, the patient had been vaccinated with CoronaVac (63). Spine magnetic resonance imaging showed longitudinally extensive transverse myelitis (TM) from the C1 to the T3 spinal cord segment (63).…”

Section: (33) Inactivated-virus Sars-cov-2 Vaccine Candidatesmentioning

confidence: 99%

Vaccination of elite athletes against SARS-CoV-2 and broader implications for public health policy

Sheehan¹

2022

Preprint

View full text Add to dashboard Cite

SARS-CoV-2, a human β-coronavirus implicated as thecausative agent in the COVID-19 pandemic, has been the subject of the most globally intensive vaccine development effort inrecorded history. The spectrum of SARS-CoV-2 vaccine candidates, deployedglobally, demonstrates an expansive diversity in regardsto design philosophies and immunological mechanisms of action. In the context of an aging, physically deconditioned, and overweight global population, which finds itself heavily burdened by a high prevalence of non-communicable chronic disease; elite strength, power and endurance athletes represent a minority population comprised of extreme physiological outliers. This report explores the molecular toxicity and pathophysiology of the SARS-CoV-2 spike protein, the design and immunological strategies embodied by the spectrum of SARS-CoV-2 vaccine candidates, and the intersection of these phenomena with the demographic, lifestyle and physiological characteristics of elite athletes; so as to inform vaccination strategies against SARS-CoV-2 which most protect this outlying minority population.

show abstract

Acute transverse myelitis after inactivated COVID-19 vaccine

Cited by 29 publications

References 0 publications

Acute autoimmune transverse myelitis following COVID-19 vaccination

Acute autoimmune transverse myelitis following COVID-19 vaccination

Acute Transverse Myelitis after COVID-19 Vaccination

Vaccination of elite athletes against SARS-CoV-2 and broader implications for public health policy

Contact Info

Product

Resources

About